

# Pierre Amarenco

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4235447/publications.pdf>

Version: 2024-02-01

118  
papers

16,311  
citations

61945

43  
h-index

23514

111  
g-index

119  
all docs

119  
docs citations

119  
times ranked

14495  
citing authors

#	ARTICLE	IF	CITATIONS
1	High-Dose Atorvastatin after Stroke or Transient Ischemic Attack. <i>New England Journal of Medicine</i> , 2006, 355, 549-559.	13.9	2,497
2	Mannheim Carotid Intima-Media Thickness and Plaque Consensus (2004-2006-2011). <i>Cerebrovascular Diseases</i> , 2012, 34, 290-296.	0.8	1,235
3	Atherosclerotic Disease of the Aortic Arch and the Risk of Ischemic Stroke. <i>New England Journal of Medicine</i> , 1994, 331, 1474-1479.	13.9	971
4	Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source. <i>New England Journal of Medicine</i> , 2018, 378, 2191-2201.	13.9	730
5	Statins in Stroke Prevention and Carotid Atherosclerosis. <i>Stroke</i> , 2004, 35, 2902-2909.	1.0	686
6	Atherosclerotic Disease of the Aortic Arch as a Risk Factor for Recurrent Ischemic Stroke. <i>New England Journal of Medicine</i> , 1996, 334, 1216-1221.	13.9	640
7	A transient ischaemic attack clinic with round-the-clock access (SOS-TIA): feasibility and effects. <i>Lancet Neurology</i> , The, 2007, 6, 953-960.	4.9	602
8	The Prevalence of Ulcerated Plaques in the Aortic Arch in Patients with Stroke. <i>New England Journal of Medicine</i> , 1992, 326, 221-225.	13.9	557
9	Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention. <i>Lancet Neurology</i> , The, 2009, 8, 453-463.	4.9	537
10	Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients. <i>New England Journal of Medicine</i> , 2017, 376, 1527-1539.	13.9	510
11	One-Year Risk of Stroke after Transient Ischemic Attack or Minor Stroke. <i>New England Journal of Medicine</i> , 2016, 374, 1533-1542.	13.9	444
12	Ticagrelor versus Aspirin in Acute Stroke or Transient Ischemic Attack. <i>New England Journal of Medicine</i> , 2016, 375, 35-43.	13.9	424
13	XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation. <i>European Heart Journal</i> , 2016, 37, 1145-1153.	1.0	383
14	Hemorrhagic stroke in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels study. <i>Neurology</i> , 2008, 70, 2364-2370.	1.5	372
15	Classification of Stroke Subtypes. <i>Cerebrovascular Diseases</i> , 2009, 27, 493-501.	0.8	350
16	A Comparison of Two LDL Cholesterol Targets after Ischemic Stroke. <i>New England Journal of Medicine</i> , 2020, 382, 9-19.	13.9	339
17	Ticagrelor and Aspirin or Aspirin Alone in Acute Ischemic Stroke or TIA. <i>New England Journal of Medicine</i> , 2020, 383, 207-217.	13.9	333
18	Lipid-Reduction Variability and Antidrug-Antibody Formation with Bococizumab. <i>New England Journal of Medicine</i> , 2017, 376, 1517-1526.	13.9	307

#	ARTICLE	IF	CITATIONS
19	Effects of Intense Low-Density Lipoprotein Cholesterol Reduction in Patients With Stroke or Transient Ischemic Attack. <i>Stroke</i> , 2007, 38, 3198-3204.	1.0	302
20	The ASCOD Phenotyping of Ischemic Stroke (Updated ASCO Phenotyping). <i>Cerebrovascular Diseases</i> , 2013, 36, 1-5.	0.8	281
21	Rationale and design of the Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT) study. <i>American Heart Journal</i> , 2018, 206, 80-93.	1.2	276
22	Atorvastatin Reduces the Risk of Cardiovascular Events in Patients With Carotid Atherosclerosis. <i>Stroke</i> , 2008, 39, 3297-3302.	1.0	243
23	Five-Year Risk of Stroke after TIA or Minor Ischemic Stroke. <i>New England Journal of Medicine</i> , 2018, 378, 2182-2190.	13.9	238
24	Clopidogrel Plus Aspirin Versus Warfarin in Patients With Stroke and Aortic Arch Plaques. <i>Stroke</i> , 2014, 45, 1248-1257.	1.0	178
25	Efficacy and safety of ticagrelor versus aspirin in acute stroke or transient ischaemic attack of atherosclerotic origin: a subgroup analysis of SOCRATES, a randomised, double-blind, controlled trial. <i>Lancet Neurology</i> , The, 2017, 16, 301-310.	4.9	174
26	Carotid Intima-Media Thickness, Plaques, and Framingham Risk Score as Independent Determinants of Stroke Risk. <i>Stroke</i> , 2005, 36, 1741-1745.	1.0	172
27	Alteplase Reduces Downstream Microvascular Thrombosis and Improves the Benefit of Large Artery Recanalization in Stroke. <i>Stroke</i> , 2015, 46, 3241-3248.	1.0	153
28	Prevalence of Coronary Atherosclerosis in Patients With Cerebral Infarction. <i>Stroke</i> , 2011, 42, 22-29.	1.0	150
29	Pathophysiology, presentation, prognosis, and management of intracranial arterial dolichoectasia. <i>Lancet Neurology</i> , The, 2015, 14, 833-845.	4.9	119
30	The selective peroxisome proliferator-activated receptor alpha modulator (SPPARM $\alpha$ ) paradigm: conceptual framework and therapeutic potential. <i>Cardiovascular Diabetology</i> , 2019, 18, 71.	2.7	104
31	Risk of Stroke and Cardiovascular Events After Ischemic Stroke or Transient Ischemic Attack in Patients With Type 2 Diabetes or Metabolic Syndrome. <i>Archives of Neurology</i> , 2011, 68, 1245.	4.9	91
32	Baseline blood pressure, low- and high-density lipoproteins, and triglycerides and the risk of vascular events in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. <i>Atherosclerosis</i> , 2009, 204, 515-520.	0.4	81
33	Aortic Arch Atherosclerosis in Patients With Embolic Stroke of Undetermined Source. <i>Stroke</i> , 2019, 50, 3184-3190.	1.0	78
34	Efficacy and Safety of Rivaroxaban Versus Aspirin in Embolic Stroke of Undetermined Source and Carotid Atherosclerosis. <i>Stroke</i> , 2019, 50, 2477-2485.	1.0	72
35	A support programme for secondary prevention in patients with transient ischaemic attack and minor stroke (INSPIRE-TMS): an open-label, randomised controlled trial. <i>Lancet Neurology</i> , The, 2020, 19, 49-60.	4.9	69
36	Ticagrelor Added to Aspirin in Acute Nonsevere Ischemic Stroke or Transient Ischemic Attack of Atherosclerotic Origin. <i>Stroke</i> , 2020, 51, 3504-3513.	1.0	67

#	ARTICLE	IF	CITATIONS
37	Underlying Pathology of Stroke of Unknown Cause (Cryptogenic Stroke). <i>Cerebrovascular Diseases</i> , 2009, 27, 97-103.	0.8	61
38	Correlation between the Framingham risk score and intima media thickness: The Paroi Artérielle et Risque Cardio-vasculaire (PARC) study. <i>Atherosclerosis</i> , 2007, 192, 363-369.	0.4	54
39	Protective Effect of High-Density Lipoprotein-Based Therapy in a Model of Embolic Stroke. <i>Stroke</i> , 2010, 41, 1536-1542.	1.0	50
40	Cyclosporine in acute ischemic stroke. <i>Neurology</i> , 2015, 84, 2216-2223.	1.5	49
41	Transient Ischemic Attack. <i>New England Journal of Medicine</i> , 2020, 382, 1933-1941.	13.9	49
42	Global Prospective Safety Analysis of Rivaroxaban. <i>Journal of the American College of Cardiology</i> , 2018, 72, 141-153.	1.2	48
43	Coronary Heart Disease Risk in Patients With Stroke or Transient Ischemic Attack and No Known Coronary Heart Disease. <i>Stroke</i> , 2010, 41, 426-430.	1.0	47
44	Overlap of Diseases Underlying Ischemic Stroke. <i>Stroke</i> , 2013, 44, 2427-2433.	1.0	42
45	Impact of Diffusion-Weighted Imaging Alberta Stroke Program Early Computed Tomography Score on the Success of Endovascular Reperfusion Therapy. <i>Stroke</i> , 2014, 45, 1992-1998.	1.0	41
46	HDL-C, triglycerides and carotid IMT: A meta-analysis of 21,000 patients with automated edge detection IMT measurement. <i>Atherosclerosis</i> , 2014, 232, 65-71.	0.4	41
47	High-Density Lipoproteins Limit Neutrophil-Induced Damage to the Blood-Brain Barrier <i>in Vitro</i> . <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2013, 33, 575-582.	2.4	39
48	Benefit of Targeting a LDL (Low-Density Lipoprotein) Cholesterol <math>\leq 70</math> mg/dL During 5 Years After Ischemic Stroke. <i>Stroke</i> , 2020, 51, 1231-1239.	1.0	39
49	Influenza vaccination and cardiovascular risk in patients with recent TIA and stroke. <i>Neurology</i> , 2014, 82, 1905-1913.	1.5	37
50	Disability after minor stroke and TIA. <i>Neurology</i> , 2019, 93, e708-e716.	1.5	36
51	Dysfunctional HDL in acute stroke. <i>Atherosclerosis</i> , 2016, 253, 75-80.	0.4	34
52	Characterization of Polymorphic Structure of Cathepsin G Gene. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2001, 21, 1538-1543.	1.1	33
53	High-density Lipoprotein-based Therapy Reduces the Hemorrhagic Complications Associated With Tissue Plasminogen Activator Treatment in Experimental Stroke. <i>Stroke</i> , 2013, 44, 699-707.	1.0	33
54	Impact of Switching From a Vitamin K Antagonist to Rivaroxaban on Satisfaction With Anticoagulation Therapy: The XANTUS-FACTS Substudy. <i>Clinical Cardiology</i> , 2016, 39, 565-569.	0.7	33

#	ARTICLE	IF	CITATIONS
55	The paradox of cholesterol and stroke. <i>Lancet</i> , The, 2007, 370, 1803-1804.	6.3	32
56	XANTUS: rationale and design of a noninterventional study of rivaroxaban for the prevention of stroke in patients with atrial fibrillation. <i>Vascular Health and Risk Management</i> , 2014, 10, 425.	1.0	29
57	Effect of High-Dose Atorvastatin on Renal Function in Subjects With Stroke or Transient Ischemic Attack in the SPARCL Trial. <i>Stroke</i> , 2014, 45, 2974-2982.	1.0	29
58	Outcomes associated with non-recommended dosing of rivaroxaban: results from the XANTUS study. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2019, 5, 70-79.	1.4	29
59	Acute Stroke or Transient Ischemic Attack Treated with Aspirin or Ticagrelor and Patient Outcomes (Socrates) Trial: Rationale and Design. <i>International Journal of Stroke</i> , 2015, 10, 1304-1308.	2.9	28
60	Association of Osteopontin, Neopterin, and Myeloperoxidase With Stroke Risk in Patients With Prior Stroke or Transient Ischemic Attacks. <i>Stroke</i> , 2017, 48, 3223-3231.	1.0	28
61	Risk for Major Bleeding in Patients Receiving Ticagrelor Compared With Aspirin After Transient Ischemic Attack or Acute Ischemic Stroke in the SOCRATES Study (Acute Stroke or Transient Ischemic) <a href="#">Tj ETQq1 1 0.784314zgBT /Over</a>	2.9	28
62	The Acute S<u>t</u>roke or Transient Isc<u>h</u>emic Attack Treated with Tic<u>a</u>gre<u>l</u>or and Aspirin for Pr<u>e</u>vention of <u>S</u>trok and Death (THALES) trial: Rationale and design. <i>International Journal of Stroke</i> , 2019, 14, 745-751.	2.9	28
63	Coronary and Basilar Artery Ectasia Are Associated. <i>Stroke</i> , 2016, 47, 224-227.	1.0	24
64	Clinical Significance of Isolated Atypical Transient Symptoms in a Cohort With Transient Ischemic Attack. <i>Stroke</i> , 2017, 48, 1495-1500.	1.0	21
65	Acute dual antiplatelet therapy for minor ischaemic stroke or transient ischaemic attack. <i>BMJ: British Medical Journal</i> , 2019, 364, l895.	2.4	21
66	Carotid Atherosclerosis Evolution When Targeting a Low-Density Lipoprotein Cholesterol Concentration <math>\leq 70</math> mg/dL After an Ischemic Stroke of Atherosclerotic Origin. <i>Circulation</i> , 2020, 142, 748-757.	1.6	21
67	Efficacy and Safety of Ticagrelor in Relation to Aspirin Use Within the Week Before Randomization in the SOCRATES Trial. <i>Stroke</i> , 2018, 49, 1678-1685.	1.0	20
68	Telemedicine for Improving Emergent Management of Acute Cerebrovascular Syndromes. <i>International Journal of Stroke</i> , 2007, 2, 47-50.	2.9	19
69	Demographics, Socio-Economic Characteristics, and Risk Factor Prevalence in Patients with Non-Cardioembolic Ischaemic Stroke in Low- and Middle-Income Countries: The OPTIC Registry. <i>International Journal of Stroke</i> , 2013, 8, 4-13.	2.9	19
70	Ticagrelor Versus Aspirin in Acute Embolic Stroke of Undetermined Source. <i>Stroke</i> , 2017, 48, 2480-2487.	1.0	19
71	Differences in Characteristics and Outcomes Between Asian and Non-Asian Patients in the TIAregistry.org. <i>Stroke</i> , 2017, 48, 1779-1787.	1.0	18
72	Aortic Sources of Embolism. <i>Frontiers in Neurology</i> , 2020, 11, 606663.	1.1	18

#	ARTICLE	IF	CITATIONS
73	High-Density Lipoprotein Therapy in Stroke: Evaluation of Endothelial SR-BI-Dependent Neuroprotective Effects. <i>International Journal of Molecular Sciences</i> , 2021, 22, 106.	1.8	18
74	Non-cardioembolic stroke/transient ischaemic attack in Asians and non-Asians: A post-hoc analysis of the PERFORM study. <i>European Stroke Journal</i> , 2019, 4, 65-74.	2.7	17
75	Intracranial and systemic atherosclerosis in the NAVIGATE ESUS trial: Recurrent stroke risk and response to antithrombotic therapy. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2020, 29, 104936.	0.7	17
76	Ticagrelor Added to Aspirin in Acute Ischemic Stroke or Transient Ischemic Attack in Prevention of Disabling Stroke. <i>JAMA Neurology</i> , 2021, 78, 177.	4.5	17
77	Five-Year Risk of Stroke after TIA or Minor Ischemic Stroke. <i>New England Journal of Medicine</i> , 2018, 379, 1579-1581.	13.9	16
78	Treat stroke to target trial design: First trial comparing two LDL targets in patients with atherothrombotic strokes. <i>European Stroke Journal</i> , 2019, 4, 271-280.	2.7	16
79	Rupture of Nonstenotic Carotid Plaque as a Cause of Ischemic Stroke Evidenced by Multimodality Imaging. <i>Circulation</i> , 2014, 129, 130-131.	1.6	15
80	Five-Year Prognosis After TIA or Minor Ischemic Stroke in Asian and Non-Asian Populations. <i>Neurology</i> , 2021, 96, e54-e66.	1.5	15
81	Low Levels of Low-Density Lipoprotein-C Associated With Proprotein Convertase Subtilisin Kexin 9 Inhibition Do Not Increase the Risk of Hemorrhagic Transformation. <i>Stroke</i> , 2014, 45, 3086-3088.	1.0	14
82	Intracranial Hemorrhage in the TST Trial. <i>Stroke</i> , 2022, 53, 457-462.	1.0	14
83	Symptomatic Patients Remain at Substantial Risk of Arterial Disease Complications Before and After Endarterectomy or Stenting. <i>Stroke</i> , 2017, 48, 1005-1010.	1.0	13
84	New prospects for PCSK9 inhibition?. <i>European Heart Journal</i> , 2018, 39, 2600-2601.	1.0	13
85	Outcomes after catheter ablation and cardioversion in patients with non-valvular atrial fibrillation: results from the prospective, observational XANTUS study. <i>Europace</i> , 2018, 20, e87-e95.	0.7	13
86	Outcome Assessment by Central Adjudicators Versus Site Investigators in Stroke Trials. <i>Stroke</i> , 2019, 50, 2187-2196.	1.0	13
87	<sc>close</sc>: Closure of patent foramen ovale, oral anticoagulants or antiplatelet therapy to prevent stroke recurrence: Study design. <i>International Journal of Stroke</i> , 2016, 11, 724-732.	2.9	12
88	Changes in High-Density Lipoproteins Related to Outcomes in Patients with Acute Stroke. <i>Journal of Clinical Medicine</i> , 2020, 9, 2269.	1.0	12
89	Methodologies for pragmatic and efficient assessment of benefits and harms: Application to the SOCRATES trial. <i>Clinical Trials</i> , 2020, 17, 617-626.	0.7	12
90	Efficacy and Safety of Ticagrelor and Aspirin in Patients With Moderate Ischemic Stroke. <i>JAMA Neurology</i> , 2021, 78, 1091.	4.5	11

#	ARTICLE	IF	CITATIONS
91	Real-world vs. randomized trial outcomes in similar populations of rivaroxaban-treated patients with non-valvular atrial fibrillation in ROCKET AF and XANTUS. <i>Europace</i> , 2019, 21, 421-427.	0.7	10
92	Protective Effect of ApoA1 (Apolipoprotein A1)-Milano in a Rat Model of Large Vessel Occlusion Stroke. <i>Stroke</i> , 2020, 51, 1886-1890.	1.0	10
93	Paracetamol, Ibuprofen, and Recurrent Major Cardiovascular and Major Bleeding Events in 19 120 Patients With Recent Ischemic Stroke. <i>Stroke</i> , 2016, 47, 1045-1052.	1.0	9
94	Ischemic Benefit and Hemorrhage Risk of Ticagrelor-Aspirin Versus Aspirin in Patients With Acute Ischemic Stroke or Transient Ischemic Attack. <i>Stroke</i> , 2021, 52, 3482-3489.	1.0	9
95	Stroke and Vascular Mortality Trends in France: 1979-2001. <i>Neuroepidemiology</i> , 2007, 29, 78-82.	1.1	7
96	Time Course for Benefit and Risk of Ticagrelor and Aspirin in Acute Ischemic Stroke or Transient Ischemic Attack. <i>Neurology</i> , 2022, 99, .	1.5	7
97	Estimated treatment effect of ticagrelor versus aspirin by investigator-assessed events compared with judgement by an independent event adjudication committee in the SOCRATES trial. <i>International Journal of Stroke</i> , 2019, 14, 908-914.	2.9	6
98	Twelve-month outcome in patients with stroke and atrial fibrillation not suitable to oral anticoagulant strategy: the WATCH-AF registry. <i>Open Heart</i> , 2019, 6, e001187.	0.9	6
99	Evaluation of non-stenotic carotid atherosclerotic plaques with combined FDG-PET imaging and CT angiography in patients with ischemic stroke of unknown origin. <i>Journal of Nuclear Cardiology</i> , 2022, 29, 1329-1336.	1.4	5
100	Time to Loading Dose and Risk of Recurrent Events in the SOCRATES Trial. <i>Stroke</i> , 2019, 50, 675-682.	1.0	3
101	Prevalence and Outcome of Potential Candidates for Left Atrial Appendage Closure After Stroke With Atrial Fibrillation. <i>Stroke</i> , 2020, 51, 2355-2363.	1.0	3
102	Minor Ischemic Stroke and a Smoldering Case of Giant-Cell Arteritis: A Case Report. <i>Stroke</i> , 2021, 52, e749-e752.	1.0	3
103	Impact of gender: Rivaroxaban for patients with atrial fibrillation in the XANTUS real-world prospective study. <i>Clinical Cardiology</i> , 2020, 43, 1405-1413.	0.7	2
104	Osteopontin Predicts Three-Month Outcome in Stroke Patients Treated by Reperfusion Therapies. <i>Journal of Clinical Medicine</i> , 2020, 9, 4028.	1.0	2
105	A Prospective, Observational Study of Rivaroxaban For Stroke Prevention In Atrial Fibrillation - The XANAP Korea. <i>Korean Journal of Internal Medicine</i> , 2021, 36, 906-913.	0.7	2
106	Adjudication of cardiovascular events in patients with chronic obstructive pulmonary disease: SUMMIT trial. <i>Clinical Trials</i> , 2020, 17, 430-436.	0.7	2
107	Aspirin's Benefits Were Previously Underestimated and Are Primarily Accrued in the Acute Setting. <i>Stroke</i> , 2017, 48, 1438-1440.	1.0	1
108	P3592 Safety analysis of rivaroxaban: a pooled analysis of the global XANTUS programme (real-world.) <i>European Heart Journal</i> , 2017, 38, .	1.0	1

#	ARTICLE	IF	CITATIONS
109	Learning from TARDIS: time for more focused trials in stroke prevention. Lancet, The, 2018, 391, 819-821.	6.3	1
110	International Collaborations Are Essential for Stroke. Stroke, 2019, 50, 2993-2994.	1.0	1
111	Temporary application of lower body positive pressure improves intracranial velocities in symptomatic acute carotid occlusion or tight stenosis: A pilot study. International Journal of Stroke, 2021, , 174749302110080.	2.9	1
112	P300Impact of gender: rivaroxaban for patients with atrial fibrillation in the XANTUS real-world prospective study. Europace, 2017, 19, iii46-iii47.	0.7	0
113	Intérêt de développer des cliniques d'IAIT en France : est-ce utile pour la santé publique ?. Bulletin De L'Academie Nationale De Medecine, 2018, 202, 275-282.	0.0	0
114	Impact of Lower Versus Higher LDL Cholesterol Targets on Cardiovascular Events After Ischemic Stroke in Patients With Diabetes. Diabetes, 2021, 70, 1807-1815.	0.3	0
115	Indications de l'occlusion de l'auricule gauche comme substitut à l'anticoagulation chez les patients qui ont un AVC lié à une fibrillation atriale: le registre WATCH-AF. Bulletin De L'Academie Nationale De Medecine, 2021, 205, 619-630.	0.0	0
116	Vascular origin in acute transient visual disturbance: A prospective study. European Journal of Neurology, 2021, 28, 4098-4108.	1.7	0
117	Risque à 3Ans, 1An et 5Ans des accidents ischémiques transitoires et infarctus cérébraux mineurs dans une cohorte contemporaine, multicentrique, multinationale, multicontinentale de 4879 patients. Bulletin De L'Academie Nationale De Medecine, 2019, 203, 315-320.	0.0	0
118	Importance du cholestérol et de son traitement dans la prévention de l'AVC. Bulletin De L'Academie Nationale De Medecine, 2020, 204, 283-291.	0.0	0